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Abstract
Background: We comprehensively analyzed X-ray cocrystal structures of dipeptidyl peptidase IV (DPP-4) and its
inhibitor to clarify whether DPP-4 alters its general or partial structure according to the inhibitor used and whether
DPP-4 has a common rule for inhibitor binding.
Results: All the main and side chains in the inhibitor binding area were minimally altered, except for a few side chains,
despite binding to inhibitors of various shapes. Some residues (Arg125, Glu205, Glu206, Tyr662 and Asn710) in the area
had binding modes to fix a specific atom of inhibitor to a particular spatial position in DPP-4. We found two specific
water molecules that were common to 92 DPP-4 structures. The two water molecules were close to many inhibitors,
and seemed to play two roles: maintaining the orientation of the Glu205 and Glu206 side chains through a network via
the water molecules, and arranging the inhibitor appropriately at the S2 subsite.
Conclusions: Our study based on high-quality resources may provide a necessary minimum consensus to help in the
discovery of a novel DPP-4 inhibitor that is commercially useful.
Keywords: Dipeptidyl peptidase IV, DPP-4 inhibitor, Inhibitory activity, Cocrystal structure, Water molecule, In silico
screening
Background
Incretin is an endogenous gut hormone that is useful in
treating patients with type 2 diabetes [1]. Incretin is se-
creted from the digestive tract with dietary intake [2]
and acts on pancreatic β-cells to stimulate insulin secre-
tion [1, 3]. Sulfonylurea, a traditional hypoglycemic drug,
promotes insulin secretion regardless of the blood glu-
cose level; because of this, it risks eliciting serious
hypoglycemia. In contrast, an antidiabetic drug that uses
incretin as a mediator is expected to reduce the risk of
hypoglycemia because stimulation of insulin secretion by
incretin depends on the blood glucose level [4].
Glucagon-like peptide-1 (GLP-1) is an incretin with
strong insulin secretion effect [5]. The active form of
GLP-1 comprises 30 amino acids [GLP-1-(7–36)NH2 or
GLP-1-(7–37)] [6], but it has a short half-life of only
2 min because two residues (His-Ala) on the N-terminus
of the active form are removed by dipeptidyl peptidase IV
(DPP-4) [7]. Currently, two different types of drugs are in
clinical use to target GLP-1. The first type is a GLP-1 ana-
log, which has a longer half-life than active endogenous
GLP-1; examples of this type include liraglutide (half-
life = 13 h) [8], exenatide (half-life = 1.3–1.6 h) [9] and
lixisenatide (half-life = approximately 2 h) [10]. The
second type is a DPP-4 inhibitor, which prolongs the half-
life of active endogenous GLP-1 by inhibiting DPP-4.
DPP-4 has strong protease activity against polypep-
tides that have an alanine or proline as a second N-
terminal residue [11]. DPP-4 inhibitor development
began with dipeptide structures that included alanine
or proline as the base. Currently, nine DPP-4 inhibi-
tors are marketed in many countries: sitagliptin [2],
vildagliptin [12, 13], alogliptin [14, 15], linagliptin
[16], anagliptin [17, 18], teneligliptin [19], saxagliptin
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[20], trelagliptin [15, 21] and omarigliptin [22]. How-
ever, these nine drugs have different structures, with
the exception of vildagliptin and saxagliptin, or alo-
gliptin and trelagliptin [23–25] (Table 1).
An explanation for why DPP-4 can accept inhibitors
of various shapes is that DPP-4 has a large cavity
(diameter ≥20 Å) [26], and these inhibitors may be
allowed to approach the active center of DPP-4. In
addition, DPP-4 has multiple binding subsites known
as the S1, S2, S1’, S2’ and S2 extensive subsites (Fig. 1)
[13]. Of the commercial drugs, vildagliptin and saxagliptin
bind to the S1 and S2 subsites, alogliptin, linagliptin and
Table 1 Structural similarity of commercial DPP-4 inhibitors (Tanimoto coefficienta)
Sitagliptin Vildagliptin Alogliptin Linagliptin Teneligliptin Anagliptin Saxagliptin Trelagliptin Omarigliptin
Sitagliptin (IC50
b : 18 nM)
-
Vildagliptin (IC50: 3.5 nM)
0.351 -
Alogliptin (IC50: 7 nM)
0.325 0.424 -
Linagliptin (IC50: 1 nM)
0.286 0.239 0.364 -
Teneligliptin (IC50: 0.37 nM)
0.261 0.300 0.341 0.413 -
Anagliptin (IC50: 3.8 nM)
0.244 0.429 0.233 0.286 0.349 -
Saxagliptin (Ki: 0.6 nM)
0.378 0.800 0.371 0.289 0.233 0.308 -
Trelagliptin (IC50: 4 nM)
0.350 0.412 0.962 0.356 0.366 0.227 0.361 -
Omarigliptin (IC50: 1.6 nM, Ki: 0.8 nM)
0.410 0.324 0.368 0.292 0.326 0.146 0.250 0.395 -
a Tanimoto coefficients were calculated by chemical structure comparison using the build-up algorithm [23]. They range from 0 to 1. When 0.8 or higher, two
structures are evaluated as similar (bold)
b IC50 and Ki were quoted from the Web Server “The Binding Database”, http://www.bindingdb.org/bind/ [24] or the Web Server “PDB bind”,
http://www.pdbbind.org.cn/ [25]
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possibly trelagliptin bind to the S1’ and/or S2’ subsites in
addition to the S1 and S2 subsites, while sitagliptin, ana-
gliptin, teneligliptin and omarigliptin bind to the S1, S2
and S2 extensive subsites. The commercial drugs effi-
ciently match the energy in these subsites and, in this
manner, probably attain high DPP-4 inhibitory activity.
It is not known if there are other causes for DPP-4
binding to inhibitors of various shapes. For example,
does DPP-4 alter its general or partial structure accord-
ing to the inhibitor used? Or, does DPP-4 have a com-
mon rule for inhibitor binding? To answer these
questions, we comprehensively analyzed X-ray cocrystal
structures of DPP-4 and its inhibitor. All the main and
side chains in the inhibitor binding area were minimally
altered, except for some side chains, despite binding to
inhibitors of various shapes. Some residues in the area
had binding modes to fix a specific atom of inhibitor to
a particular spatial position in DPP-4. We found two
specific water molecules that were common to many
DPP-4 structures. The two water molecules were close
to many inhibitors, and seemed to be related to inhibitor
binding. This information may provide a necessary mini-
mum consensus to help in the discovery of a novel DPP-
4 inhibitor that is commercially useful.
Methods
Data collection
We collected X-ray cocrystal structures of human
DPP-4 and its inhibitor that were registered with the
Protein Data Bank (PDB) [27] until 2015. Sixty-eight
PDB codes that had a resolution of less than 3 Å
were used (Additional file 1: Figure S1). Most of the
PDBs had a crystallization temperature that ranged
from 277 K to 298 K and an X-ray diffraction-
measured temperature range from 90 K to 120 K.
However, the X-ray diffraction of only five PDBs
(PDB ID: 2AJL, 2I03, 2I78, 2OLE and 3EIO) was
measured at a high temperature (in the range of
200 K to 298 K) (Additional file 2: Table S1).
One, two or four DPP-4 molecules are included
per one PDB code. The DPP-4 molecule that had an
inhibitor bound to the DPP-4 active center and that
had less than six disordered residues was selected
from each PDB code. We defined the coordinates of
one DPP-4 molecule (724 residues: residue 41–764)
with one inhibitor on the active center and water O
atoms within 4 Å from the DPP-4 molecule as one
unit (we will discuss the distance between heavy
atoms). Ultimately, there were 147 inhibitor-bound
units identified from the 68 PDBs (i.e., 68 kinds of
inhibitors). To compare and evaluate the inhibitor-
bound units, we also collected X-ray crystal struc-
tures of inhibitor-free human DPP-4 that had a reso-
lution of less than 3 Å. Eight inhibitor-free units
were identified from four PDB codes (PDB ID: 1J2E,
1NU6, 1PFQ and 1TK3) (Additional file 2: Table S1).
These units were used for the procedure discussed
below.
Fig. 1 Inhibitor binding area of DPP-4. Representative image from the cocrystal structure of sitagliptin and DPP-4 (PDB ID: 1X70). The carbon skeleton
of sitagliptin is represented by green stick. The carbon skeleton of 14 residues is labeled and represented by yellow stick. Val656 and
Trp659 are positioned on the opposite side of view in this Figure; thus, they are not shown. O, N, and halogen atoms are labeled in red,
blue and light blue sticks, respectively. The subsites, which are directly involved with binding to inhibitors (S1, S1′, S2, S2′ and S2 extensive), are labeled
in orange
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Defining the DPP-4 inhibitor binding area
Generally, some kinds of interactions (e.g., hydrogen
bond, electrostatic interaction, hydrophobic interaction
and π–π stacking effect) are considered to occur be-
tween two heavy atoms that are close to each other (less
than c.a. 4–5 Å). In DPP-4, 13 residues (Arg125, Glu205,
Glu206, Phe357, Tyr547, Ser630, Tyr631, Val656,
Tyr662, Tyr666, Asn710, Val711 and His740) were close
to (<4 Å) at least 48 out of the 68 inhibitors (>70 %) and
three residues (Ser209, Arg358 and Trp659) were close
to (<4 Å) at least 21 out of the 68 inhibitors (>30 %).
We defined the above 16 residues as the DPP-4 inhibitor
binding area (Fig. 1).
Cα atom variation between units
We calculated Cα atom variation between units as
follows:
[Step 1] From the above-mentioned units, two units
were selected.
[Step 2] The two units were superimposed so that the
root mean square deviation (RMSD) targeting Cα
atoms of the DPP-4 molecule (residue 41–764) would










where χi represents the distance of the i
th atom between
the two units, and N represents the number of equiva-
lent atom pairs. In this procedure, only the Cα atom was
applied to Eq. (1). The minimum RMSD indicates the
global deviation of DPP-4 structure between the two units
(the minimum RMSD value will be referred to as RMSD).
A graphics software program, PyMOL (Schrödinger, Inc.,
New York, NY, USA), was used for superposition [28].
[Step 3] Steps 1 and 2 were conducted for every com-
bination. When targeting 147 inhibitor-bound units,
there are 10,731 combinations.
[Step 4] After optimum superposition for all combina-
tions was achieved, the average distance of the ith Cα
atom between two units was calculated using Eq. 2, and
defined as the ith Cα atom variation between units.






where δik is the distance of the i
th atom for the kth com-
bination between two units, and M represents the number
of combinations. When targeting 147 inhibitor-bound
units, M is 10,731.
Side chain variation between units
Side chain variation between units was calculated as
follows:
[Step 1] From the above-mentioned units, two units
were selected.
[Step 2] The two units were superimposed so that the
RMSD of main chain (N, Cα and C atoms) of the ith
residue would be minimized (Eq. 1 was used). The
minimum RMSD calculated here represents the main
chain deviation of the ith residue between the two units.
[Step 3] Steps 1 and 2 were conducted for every
combination.
[Step 4] After superposition for all combinations, the
average distance of a specific side chain atom (e.g., the
serine Oγ atom) between two units was calculated
using Eq. 2 from the previous procedure. This was
defined as the side chain variation of the ith residue
between units.
Calculating the exposed surface area
The exposed surface area per one residue of one unit
was calculated. In the calculation, water O atoms and
the inhibitor were excluded from the unit. The ex-
posed surface area was determined using the Web
Server GETAREA (Sealy Center for Structural Biology,
University of Texas Medical Branch, Galveston, TX, USA)
[29]. For each residue, an average of 147 inhibitor-bound




The average RMSD targeting Cα atoms between 147
inhibitor-bound units was 0.48 Å and the maximum
RMSD was 0.98 Å. Considering that the minimum reso-
lution of the adopted structures, that is the minimum
coordinate error of the structures used, is 1.62 Å (PDB
ID: 4A5S, [30]) and that DPP-4 is a large molecule com-
posed of more than 700 residues, we suggest that even
the maximum RMSD is below the measurement error
range and the units examined are all similar. Keedy et al.
reports that the crystal structure of a protein is affected
more by cryocooling than by the lab performing the
experiment [31]. Eight units (PDB ID: 2AJL_I, 2AJL_J,
2I03_B, 2I78_B, 2OLE_A, 2OLE_B, 3EIO_A and
3EIO_B) were measured in X-ray diffraction at a higher
temperature (in the range of 200 K to 298 K) than the
other inhibitor-bound units (Additional file 2: Table S1),
but the high temperature-measured units were not large
in the average RMSD compared with the other units (in
the range from 0.46 Å to 0.56 Å). This result suggests
that DPP-4 global structure is not changed in the
temperature range from 90 to 298 K.
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The RMSD measures global deviation between units,
but cannot identify partial deviation within molecule.
Thus, each Cα atom variation between units was calcu-
lated and presented in the order of the exposed surface
area (Fig. 2). Generally, in a large molecule, the surface
(outside) is more variegated than the inside because the
former is more affected by the external environment
(e.g., a crystal forming condition or measurement
temperature) than the latter. The larger the exposed sur-
face area, the more frequently Cα atoms with a large
variation were found in the DPP-4 structure. However,
all residues in the inhibitor binding area had a less vari-
ation than the mean variation of the 724 residues
(0.37 Å, Fig. 2), indicating that the main chain structure
of the inhibitor binding area was only slightly altered
according to the inhibitor used.
Side chain variation
Side chain variation was classified for each amino acid
class and presented in the order of the exposed surface
area (Fig. 3). We also visually observed the superposition
of 147 inhibitor-bound units (Fig. 4). In the inhibitor
binding area, the side chains of Arg358, Tyr547 and
Ser630 had a larger variation compared with the average
of the equivalent amino acids (Fig. 3a, b and c).
The Arg358 side chains were oriented in a disorderly
manner (Fig. 4a). This disorder was found in the
inhibitor-free units (Additional file 3: Figure S2a).
Arg358 constitutes a part of the S2 extensive subsite,
and out of 68, 21 inhibitors (out of 147 inhibitor-bound
units, 34 units) were close to this residue (<4 Å). How-
ever, there was no trend in the orientation of the Arg358
side chains, even when focusing on only the 34 units
(the Nη atoms are colored cyan in Fig. 4a). These results
indicate that the Arg358 side chain has no specific
orientation regardless of the presence/absence of
inhibitor. To inquire into the cause of this large vari-
ation, we compared Arg358 with Arg125 whose side
chain had the minimum variation (Fig. 4a and b).
Arg125 had concentrated distributions of some water O
atoms surrounding the whole of residue (Fig. 4b),
whereas Arg358 had no concentrated distribution of
water O atom surrounding the Nη atoms (Fig. 4a). The
exposed surface area of Arg125 is larger than that of
Arg358 at first sight, but the Arg125 side chain may be
fixed because it is surrounded by some fixed hydrated
water molecules. On the other hand, the perimeter of
the Arg358 Nη atoms is free from hydrated water, and
therefore the orientation of the Arg358 side chain may
be flexible.
The Tyr547 benzene rings had their orientation depo-
larized (Fig. 4c and d). Sheehan et al. reports that the
Tyr547 χ1 dihedral angle changes by 70° between the
two orientations [32]. The Tyr547 benzene rings of the
inhibitor-free units showed only one direction (Add-
itional file 3: Figure S2b), and this direction was similar
to that of one group of the inhibitor-bound units (Fig. 4c:
the first group, the Oη atoms are colored red). The other
group (Fig. 4d: the second group, the Oη atoms are col-
ored cyan) had aromatic ring of the inhibitors stacked
on the Tyr547 benzene ring. In the commercial drugs,
sitagliptin, saxagliptin, trelagliptin, vildagliptin, anaglip-
tin and omarigliptin were the first group, whereas lina-
gliptin and alogliptin were the second group. These
results suggest that the Tyr547 benzene ring could shift
to a different direction from the original direction ob-
served for the inhibitor-free units to obtain π-π stacking
interaction with inhibitor. The π-π stacking interaction
of the Tyr547 benzene ring has been reported by many
studies [13–16, 30, 32–39]. However, the Tyr547 hy-
droxyl group in the original direction sometimes electro-
statically interacts with the inhibitor’s polar group or





























































Fig. 2 Cα atom variations of DPP-4. Residues in the inhibitor binding area are labeled (red columns). Cα atom variations of residues in
the inhibitor binding area are below the average variation of all Cα atoms in DPP-4 (0.37 Å, dashed black line). Cα atoms are listed in
the order of their exposed surface area. The vertical axis on the left side is the exposed surface area (blue line graph) and the vertical
axis on the right side is the variation value (green bar and red column graph)
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The S630 Oγ atoms were oriented in all directions
(Fig. 4e). This disorder was found in the inhibitor-free
units (Additional file 3: Figure S2c). Ser630 is the active
center of DPP-4 and was positioned within 4 Å from all
68 inhibitors. Some inhibitors have a cyanopyrrolidine,
in which the nitrile C atom covalently bonds to the
Ser630 Oγ atom. In this case, the Ser630 Oγ atom was
naturally oriented toward the inhibitor and very close to
the inhibitor nitrile C atom (<3 Å, the Oγ atom is
colored cyan in Fig. 4e) (PDB ID: 2AJL [42], 2G5P,
2G5T, 2G63 [33], 2I03 [43], 3BJM (saxagliptin) [20] and
3W2T (vildagliptin) [13]). However, for inhibitors that
Fig. 3 Side chain variations of DPP-4. Sixteen residues in the inhibitor binding area are labeled (red columns). Thirteen residues (Arg125, Tyr 631,
Tyr 662, Tyr 666, Ser209, Val656, Val711, Asn710, Glu205, Glu206, His740 and Phe357 and Trp659) have their side chain variations below the average
variation of the equivalent amino acids (dashed black line). Specific atoms that are positioned furthest from the main chain were calculated to be the
variation. The graph shows the variations for each amino acid and they are listed in the order of the exposed surface area. The vertical
axis on the left is the exposed surface area (blue line graph) and the vertical axis on the right is the variation value (green bar and red col-
umn graph). The variations of the two Arg Nη atoms, the two Glu Oε atoms and the two Val Cγ atoms are averaged, respectively. a Arg Nη atom, b
Tyr Oη atom, c Ser Oγ atom, d Val Oγ atom, e Asn Nδ atom, f Glu Oε atom, g His Nε atom, h Phe Cζ atom and i Trp Cη atom
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Fig. 4 Superposition of some residues in the inhibitor binding area. In each residue, 147 inhibitor-bound units are superimposed so that the
RMSD targeting main chain (N, Cα and C atoms) would be minimized based on a specific inhibitor-bound unit. Excluding some exceptions, O
and N atoms are colored red and blue, respectively, and the carbon skeleton of inhibitors is shadowed in green. a Arg358: The units close to the
inhibitor (<4 Å) have the Nη atom colored cyan and the water O atom colored yellow. b Arg125. c and d Tyr547: The Tyr547 side chains were
divided into c the first and d the second group. In the second group, the Oη atom is colored cyan and the water O atom is colored yellow.
e Ser630: The units in which inhibitor forms a covalent bond have the Oγ atom colored cyan, the inhibitor drawn by a line and the water O atom
colored yellow. The image of the different angle is drawn at the lower left in this Figure. f Ser209: Some units close to the inhibitor (<4 Å) have
the Oγ atom colored cyan and the water O atom colored yellow. g Var711: The units in which the Cγ atoms have an opposite direction to the
other units have the Cγ atom marked by a “sphere”. h Asn710: Some units in which the Oδ and Nδ atoms are switched to each other have the
water O atom colored yellow
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do not require a covalent bond, the Ser630 Oγ atom
seems to be oriented in a disorderly manner. This result
suggests that the important thing for DPP-4 inhibitor
may be in preventing GLP-1 from approaching Ser630
spatially rather than in deactivating Ser630 directly. Sax-
agliptin and vildagliptin are commercial covalent bond
drugs, but they do not always have a higher potency
than the other noncovalent bond commercial drugs
(Table 1). This may be because DPP-4 itself slowly
hydrolyzes their covalent bond and finally deactivates
the covalent bond drugs [44].
The side chains of Ser209, Asn710 and Val711 did not
have a significantly large variation compared with the
average of the equivalent amino acids (Fig. 3c, d and e),
but the superposition of the equivalent amino acids re-
vealed irregular orientational alternatives (Fig. 4f, g and
h). In the inhibitor-free units, the Ser209 and Val711
side chains showed the regular orientations (Additional
file 3: Figure S2d and e). The Ser209 side chains had no
trend when “close to inhibitor” (<4 Å, the Oγ atoms are
colored cyan in Fig. 4f ) and “not close to inhibitor” (the
Oγ atoms are colored red in Fig. 4f ) were compared.
Val711 had only four units (3O95_B, 3O95_D, 3O9V_B
and 3O9V_D) in which the Cγ atoms were irregularly
oriented against the other inhibitor-bound units (the Cγ
atoms are marked by sphere in Fig. 4g), but this irregu-
larity was found in a PDB (3O95_B and 3O95_D vs.
3O95_A and 3O95_C, 3O9V_B and 3O9V_D vs.
3O9V_A and 3O9V_C) despite having the same inhibitor.
The reason that irregular orientations appeared for the
Ser209 and Val711 side chains is unclear, although it is
possible that the inhibitor influences their orientations.
Asn710 had 47 units in which the Nδ and Oδ atoms
were switched to each other compared to the other
inhibitor-bound units (Fig. 4h). In the commercial drugs,
only linagliptin and alogliptin contained the switched
Asn710. This trend was found in the inhibitor-free units
(Additional file 3: Figure S2f ). There were two fixed
water O atoms found in both of the inhibitor-bound/free
units, but their positions were not changed by switching
the Nδ and Oδ atoms (Fig. 4h). No units had the inhibi-
tor N atom close to (<4 Å) the switched/non-switched
Nδ atom of Asn710 (data not shown). This result sug-
gests a tendency that the Nδ and Oδ atoms of Asn710
are switched to each other so that the Nδ atom does not
approach too close to the inhibitor’s N atom.
The side chains of the above six residues may be flexible
or have orientational alternatives according to the inhibi-
tor used. However, the side chains of the other 10 residues
(Arg125, Glu205, Glu206, Phe357, Tyr631, Val656,
Trp659, Tyr662, Tyr666 and His740) had a less variation
than the average of the equivalent amino acids (Fig. 3),
and the superposition of the equivalent amino acids
showed that their side chains had little orientational
difference between units (data not shown). These results
suggest that the side chains of the 10 residues are mostly
unaltered according to the inhibitor used. Little move-
ment of the DPP-4 inhibitor binding area through the
superposition of some X-ray cocrystal structures with
different inhibitors has been described in some studies
[35, 41, 45], and they are consistent with our suggestions.
The observed rigidity is not a crystal property but probably
a DPP-4 property because the collected structures were
from different constructs and from different crystal forms,
as many researchers have suggested.
Common binding modes between DPP-4 and inhibitors
We searched electrostatic binding modes between DPP-4
and its inhibitors. In the DPP-4 inhibitor binding area,
binding modes of Arg125, Glu205, Glu206, Tyr662 or
Asn710 were common between many inhibitors.
Out of 68 inhibitors, 67 had a primary or secondary
amino N atom close to one of two Glu205 Oε atoms
(<4 Å, dashed yellow lines in Fig. 5a) and one or
both of the two Glu206 Oε atoms (<4 Å, dashed cyan
lines in Fig. 5a). The exception was 1TKR because
the inhibitor in 1TKR has no N atom. In addition,
the 67 inhibitors had the same N atom close to the
Tyr662 Oη atom (<5 Å, dashed magenta lines in Fig. 5a).
This network has been reported to be important for
DPP-4 inhibitor to bind to the DPP-4 active center
[2, 13–17, 20, 22, 30, 32–37, 40–42, 45–62]. The side
chains of the three residues were oriented in a pre-
determined direction, as discussed above. This means
that a primary or secondary amino group of inhibitor
is present without exception at a particular spatial
position in DPP-4 and forms binding modes with the
Glu205, Glu206 and Tyr662 side chains, suggesting
that these binding modes may be a powerful rule for
DPP-4 inhibitor to maintain stable binding with DPP-4.
Of 68 inhibitors, 53 had an O, N or halogen atom
close to at least one of the Arg125 Nη atoms (Fig. 5b,
dashed yellow lines, < 4 Å) and the Asn710 Nδ or Oδ
atom (Fig. 5b, dashed magenta lines, < 4 Å). As men-
tioned above, the Arg125 and Asn710 side chains were
oriented in a pre-determined direction, although pos-
ition switching between the Oδ and Nδ atoms of
Asn710 occurred in some units. The network of Asn710
and/or Arg125 also has been described by many authors
[20, 32, 34, 35, 40, 41, 49, 52, 55, 56]. However, for the
commercial drugs, only linagliptin (PDB ID: 2RGU [16])
had no binding mode with Arg125 and Asn710, and
therefore this network may be less important than that
with Glu205, Glu206 and Tyr662.
The Ser630 Oγ atom was also close to the polar atom
of many inhibitors, but there were minimal common
characteristics found on the inhibitor side. The dis-
orderly orientation of the Ser630 Oγ atom was discussed
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above, suggesting that the placement of an inhibitor with
an excluded volume effect close to the Ser630 hydroxyl
group is a main role for some DPP-4 inhibitors.
Common water molecules between units
When two units were superimposed, water O atoms
within 1 Å were defined as identical. 2OQI_B, 2OQV_A,
3F8S_A and 3F8S_B had no registered water O atoms.
Two hundred thirty-eight water O atoms corresponded to
the above identical definition in at least 61 out of the
remaining 143 inhibitor-bound units. Among these, 26
water O atoms were close to the inhibitor binding area
(<4 Å), and two specific water O atoms were also close to
many inhibitors (<5 Å, red spheres in Fig. 6).
The first specific water O atom was observed in 108
inhibitor-bound units (blue circles and red triangles in
Fig. 7). It was close to 52 inhibitors (<5 Å, dashed cyan
lines in Fig. 6), the His126 Nε, the Glu205 Oε and the
Ser209 Oγ atoms (<4 Å, dashed bold yellow lines in
Fig. 6). This water molecule has been described in some
studies [13, 45, 63]. The second specific water O atom was
also observed in 108 units (blue and yellow circles in
Fig. 7). It was close to 55 inhibitors (<5 Å, dashed magenta
lines in Fig. 6), the Glu206 Oε and the Arg669 Nη atoms
(<4 Å, dashed bold yellow lines in Fig. 6). Ninety-two units
had both of the two water O atoms (blue circles in Fig. 7).
Many of the inhibitor-bound units that lack either of
the two specific water O atoms were distributed over
2.5 Å resolution (red triangles, and yellow and grey cir-
cles in Fig. 7). Nineteen units that did not have the two
O water atoms (grey circles in Fig. 7) showed few regis-
tered water O atoms (the maximum was 129 water O
Fig. 6 Two specific water O atoms close to inhibitors (red spheres).
Both of the two water O atoms were found in 108 inhibitor-bound
units. When superimposed so that the RMSD targeting Cα atoms in
DPP-4 (residue 41–764) would be minimized based on 1X70_A, water
O atoms in the unit were simultaneously superimposed. The carbon
skeleton of inhibitors is shown with green line. O, N and halogen
atoms are colored red, blue and pale cyan, respectively. The DPP-4
structure was obtained from the coordinates of PDB ID 1X70.
The distances between inhibitors and the first specific water O
atoms (No. 1) are shown with dashed cyan lines. The distances
between inhibitors and the second specific water O atoms (No. 2) are
shown with dashed magenta lines. The distances between the two
water O atoms and His126, Glu205, Gul206, Ser209 or Arg669 are
shown with dashed bold yellow line. Phe357 (yellow area) forms a
large wall at the S2 subsite
Fig. 5 Superposition of DPP4 inhibitors highlights the important
binding interactions to some residues. When the inhibitor-bound
units were superimposed so that the RMSD targeting Cα atoms in
DPP-4 (residue numbers 41–764) would be minimized based on
4PNZ_A, 68 types of inhibitors were simultaneously superimposed.
The carbon skeleton of inhibitors is indicated by green line. O, N
and halogen atoms are colored red, blue and pale cyan, respectively.
a Binding modes between Glu205, Glu206 or Tyr662 and inhibitors.
The distances between a primary or secondary amino N atom of
inhibitor and the Glu205 Oε atom (<4 Å, yellow), the Glu206 Oε atom
(<4 Å, cyan), or the Tyr662 Oη atom (<5 Å, magenta) are shown with
dashed lines. b Binding modes between Arg125 or Asn710 and
inhibitors. The distances between an O, N or halogen atom of
inhibitor and the Arg125 Nη atom (<4 Å, yellow) or the Asn710
Oδ/Nδ atom (<4 Å, magenta) are shown with dashed lines
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atoms, dashed line in Fig. 7). These results suggest that
the two specific water O atoms were overlooked in the
units because their positions could not be identified ac-
curately. Keedy el al. reports that the ordering of
surface-associated waters is driven by cryocooling [31].
However, the high temperature-measured units had two
water O atoms in the same position as the other inhibi-
tor-bound units (Additional file 4: Figure S3), and the
two specific water O atoms were also found in the
inhibitor-free units (Additional file 5: Figure S4). The B-
factor is an index of atom thermal mobility within crystal
structure. In many inhibitor-bound units, both of the two
specific water O atoms had a lower B-factor than the
average B-factors of all water O atoms and of all pro-
tein heavy atoms (Additional file 6: Table S2 and
Additional file 7: Table S3). Generally, hydrated water
that is usually entrapped from local protein structure
has a lower B-factor than crystal water that is acci-
dentally entrapped by crystallization. The above two water
molecules we found seem to exist as hydrated water that
is taken into the local position in inherent DPP-4, inde-
pendently of a temperature change (ranged from 90 to
298 K) and regardless if DPP-4 has an inhibitor.
The primary role of the two specific water molecules
(probably hydrated water) may be forming an electro-
static network with His126, Glu205 and Ser209, and
with Glu206 and Arg669, and maintaining the orienta-
tion of the side chains of Glu205 and Glu206 through
the network may be especially important for inhibitor
binding. The adamantan hydroxyl group of vildagliptin
is reported to interact with the first specific water mol-
ecule [13], and it may be important for the potency of
vildagliptin. The two water molecules, however, do not
seem to have an electrostatic interaction with many in-
hibitors because they are close to the carbon skeleton of
the inhibitors rather than to their polar atoms. All 68 in-
hibitors were placed as if they were avoiding the position
of the two water O atoms. The secondary role of the
two water molecules may be an excluded volume effect,
such as arranging inhibitor appropriately at the S2 sub-
site. The two water O atoms were located at the bottom
of the S2 subsite, where Phe357 formed a large wall at
the S2 subsite (yellow area in Fig. 6). The hydrophobic
or π-π stacking interaction of the Phe357 benzene ring
has been reported to be important for binding in many
inhibitors [2, 17, 22, 33, 42, 45, 47–49, 51–55, 57, 60,
64]. Further research is needed to determine the de-
tailed relationship between the two specific water
molecules and inhibitor potency. However, the pre-
arrangement of the two water molecules should be
considered in in silico screening not to lead inhibitor
to improper position.
It has been often asked whether hydrated water in
a crystal structure is applicable in solution. Generally,
crystal and hydrated water occupies an average of
50 % of the crystal structure, and many protein crys-
tal structures have been reported to reflect the struc-

































Fig. 7 Correlation between X-ray diffraction resolution and the number of water O atoms registered. Ninety-two units (blue circles) have both of
the two specific water O atoms. Sixteen units (red triangles) have only the first specific water O atom (the first red sphere in Fig. 6), and 16 units
(yellow circles) have only the second specific water O atom (the second red sphere in Fig. 6). Nineteen units (grey circles) have neither of the
two water O atoms, and 2OQI_B, 2OQV_A, 3F8S_A and 3F8S_B (grey circles) have no registered water O atoms. The unit that contains the most
water O atoms in the above 19 units (grey circles) is PDB ID 3O95_B (129 water O atoms, dashed line)
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dynamics simulation showed that the frequent appear-
ance positions of water molecule during the simula-
tion agrees with the hydrated water site in the X-ray
crystal structure [78]. However, whether the two spe-
cific water molecules are necessary for an inhibitor to
maintain stable binding with DPP-4 should be con-
firmed by a solution structure using nuclear magnetic
resonance (NMR) or molecular dynamics simulation
(the solution structure of DPP-4 has not yet been ob-
tained using NMR). A few molecular dynamics simu-
lations have reported the interaction between DPP-4
and its inhibitor [79, 80], but further simulations
evaluating hydrated water require additional research,
which we plan to perform in the future.
DPP-4 inhibitory affinity of the inhibitor used
The results so far were provided based on only crystal
structures whose resolutions were less than 3.0 Å to pro-
vide high-quality information (Additional file 2: Table S1).
However, if the results are used by in silico screening, a
realistic potency should accompany the candidates that
passed the screening test. DPP-4 inhibitory activity of
PDBs (inhibitors) that we collected ranged from 0.1 to
30,000 nM in IC50/Ki, and many of them had high inhibi-
tory activity of less than 30 nM (Additional file 8: Table
S4) [24, 25]. This value is a standard of the commer-
cial drugs, as shown by Table 1. Thus, we used high-
quality resources in regard to resolution and DPP-4
inhibitory affinity. Therefore, our study provides ne-
cessary information for in silico screening, and may
provide a necessary minimum consensus to help in
the discovery of a novel DPP-4 inhibitor that is com-
mercially useful. However, DPP-4 inhibitor also needs
to meet some optional requirements to acquire sub-
stantial commercial-drug level inhibitory activity, e.g.
geometric fitness and electrostatic/non-electrostatic
interaction with some subsites.
Conclusions
To clarify whether DPP-4 alters its general or partial
structure according to the inhibitor used and whether
DPP-4 has a common rule for inhibitor binding, we
comprehensively analyzed X-ray cocrystal structures of
DPP-4 and its inhibitor. Before beginning this research,
we expected that DPP-4 would alter at least its partial
structure because DPP-4 can bind to inhibitors of vari-
ous shapes. However, our results were different from our
initial expectations. All the main and side chains in the
inhibitor binding area were only minimally altered ex-
cept for some side chains (Ser209, Arg358, Tyr547,
Ser630, Val656 and Asn710), despite binding to inhibi-
tors of various shapes. Some residues (Arg125, Glu205,
Glu206, Tyr662 and Asn710) in the area had binding
modes to fix a specific atom of inhibitor to a particular
spatial position in DPP-4. We found two specific water
molecules that are common to 92 DPP-4 crystal struc-
tures. The two water molecules were close to many in-
hibitors, and seemed to play two roles: maintaining the
orientation of the Glu205 and Glu206 side chains, which
is important for inhibitor binding through an electro-
static network via the two water molecules, and arran-
ging the inhibitor appropriately at the S2 subsite. In this
study, we used high-quality resources, and therefore this
information may provide a necessary minimum consen-
sus to help in the discovery of a novel DPP-4 inhibitor
that is commercially useful.
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